

U-M Institutional Biosafety Committee
Draft Minutes
Approved at the August 21, 2026, IBC Meeting

Meeting Information:

Date: Friday, July 17, 2026

Time: 1:15-2:30 p.m.

Location: Via conference call (Zoom)

Voting Members Present: Jessica Bunn (alt. for Jones), Steven Clark, Wanlu Du, Chris Fenno, Huiira Kopera, Joyce Lai, Patrick Lester, Jon Oscherwitz, Stephen Rapundalo, Alex Rickard, Yifan Wang, Fei Wen, Christiane Wobus (Chair)

Voting Members Absent: Pamela Bennett-Baker, Matt Chapman, Sheya Jones, Tom Lanigan, Jonny Sexton, Jackie Shields, Andrew Tai

Alternate Members Present: Ingrid Bergin (alt. for Lester)

IBC Staff Members Present: Jen Harley, Michael Santiago-Castro, Alicia Trombley

Guests Present: Carolyn Kuenz, Nicoleen Boyle, Andrew Kennedy, Em SeGraves, Kathy Ignatoski, Pat Ward

The meeting was called to order at: 1:16 p.m.

The meeting was adjourned at: 1:41 p.m.

Agenda Items:

1. Updates from the Chair – Christiane Wobus

Dr. Wobus introduced new committee members Steven Clark, Jonny Sexton, and Yifan Wang.

2. Consideration of minutes from the previous meeting

The committee reviewed the minutes from the June 19, 2026, meeting. There were no changes recommended.

Motion: Stephen Rapundalo moved to approve the minutes.

Second: Chris Fenno seconded the motion.

Vote: All in favor.

3. Biosafety Officer Report – Andrew Kennedy (in place of Sheya Jones)

Mr. Kennedy described an incident that involved a waste vendor employee receiving a needle stick injury due to improperly disposed sharps. At the time of the meeting, the EHS Biosafety team and U-M HazMat team were working to determine what substance may have been in the syringe. A preliminary report was sent to NIH OSP and a follow-up report will be submitted as soon as possible. EHS Biosafety will also be working to distribute additional educational materials surrounding proper sharps disposal.

4. Conflict of interest disclosure opportunity

Dr. Wobus asked committee members whether they or their labs were involved with, or were in conflict with, financially or otherwise, any items on today's agenda.

1. Christiane Wobus indicated a conflict with application IBCA00000756_AR15 for Dr. Wigginton and IBCA00000787_AR06 for Dr. Shah.
2. Alex Rickard indicated a conflict with application IBCA00000756_AR15 for Dr. Wigginton and IBCA00002363 for Dr. Draelos.

5. Applications for committee action

BSL2 Applications

The following BSL2 applications were considered and voted upon separately by the committee due to a conflict of interest. Chris Fenno chaired this portion of the meeting.

11. IBCA00000756_AR15

Wigginton, Krista – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (influenza viral vectors); BSL1 (RG1 viruses and bacteria); BSL2 (RG2 viruses); BSL2 (human- and animal-derived substances from non-human primates). No work involving biological toxins, animals, or plants.

Changes: Added work with *Pseudomonas aeruginosa* (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application, favorable review from one reviewer, and favorable re-review from one reviewer.

12. IBCA00000787_AR06

Shah, Yatrik – Renewal

Current approval: BSL1 (plasmid, AAV vectors and vectorless systems); BSL2 (adenoviral, lentiviral, and MSCV vectors); BSL1 (*Citrobacter rodentium*); BSL2 (*Salmonella typhimurium*); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered Diphtheria toxin or plasmid vectors); ABSL2 for 3 days (mice administered adenovirus or AAV vectors); ABSL2 for the duration (mice administered human-derived substances or RG1/RG2 bacteria). No work involving biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

Motion: Joyce Lai moved to approve the (2) applications listed above, at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Fei Wen seconded the motion.

Vote: All in favor, with Christiane Wobus and Alex Rickard recused.

Christiane Wobus resumed chairing the meeting.

25. IBCA00002363**Draelos, Mark - Initial Application**

Proposed: BSL2 (human-derived substances); BSL1 (animal-derived substances: swine and chickens); BSL2 (animal-derived substances: ruminants). No work involving rDNA, infectious agents, biological toxins, animals or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable re-review from one reviewer.

Motion: Stephen Rapundalo moved to approve the (1) applications listed above, at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Chris Fenno seconded the motion.

Vote: All in favor, with Alex Rickard recused.

The following BSL2 applications were considered by the committee and voted upon:

1. IBCA00000026_AR10**Brady, Graham – Amendment**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice and zebrafish). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added work with new gene elements in plasmid vectors (BSL1), work with AAV vectors (BSL1) with administration to mice (ABSL1), and work with adenovirus vectors (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

2. IBCA00000047_AR03**Fink, John – Renewal**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (Epstein-Barr virus); BSL2 (human-derived substances); ABSL1 (transgenic rodents and fruit flies); ABSL1 (vectorless systems administered to rodents). No work involving biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

3. IBCA00000072_AR04**Wang, Thomas – Amendment**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added administration of rDNA-modified animal cells to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

4. IBCA00000130_AR08**Mehta, Geeta – Renewal**

Current approval: BSL1 (vectorless systems, plasmid vectors and AAV vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances and animal-derived substances from swine and chickens); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, or plants.

Changes: Added additional work with human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

5. IBCA00000165_AR06**Weisman, Lois – Amendment**

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (adenoviral and lentiviral vectors); BSL2 (TTX); BSL2 (human-derived substances). No work involving infectious agents, animal-derived substances, animals, or plants.

Changes: Added work with transgenic mice (ABSL1).

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

6. IBCA00000465_AR13**MacDougald, Ormond – Amendment**

Current approval: BSL1 (plasmid vectors and AAV vectors); BSL2 (lentiviral, MMLV, adenoviral, and AAV vectors with growth control genes); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic rodents); ABSL1 (mice administered plasmid vectors, AAV vectors, or LPS); ABSL2 for 3 days (mice administered AAV vectors with growth control genes). No work involving infectious agents, animal-derived substances, or plants.

Changes: Added administration of rDNA-modified animal cells to mice (ABSL1) and human-derived substances to mice (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

7. IBCA00000472_AR07**Corfas, Gabriel – Renewal**

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (adenovirus and retrovirus vectors; AAV vectors with growth control genes); BSL2 (Diphtheria toxin); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors or Diphtheria toxin; guinea pigs administered AAV vectors). No work involving infectious agents, human- or animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

8. IBCA00000483_AR06**Tiba, Mohamad – Renewal**

Current approval: BSL2 (pathogenic E. coli); BSL2 (LPS); BSL1 (animal-derived substances from

swine); ABSL1 (pigs administered animal-derived substances or LPS); ABSL2 for the duration (pigs administered pathogenic *E. coli*). No work involving rDNA, human-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

9. IBCA00000553_AR12

Wiley, John – Renewal

Current approval: Current approval: BSL1 (vectorless systems, plasmid and AAV vectors); BSL2 (lentiviral, rabies, pseudorabies, and AAV vectors with growth control genes); BSL1 (RG1 bacteria); BSL2 (LPS and Lipoteichoic Acid); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (rodents administered LPS, RG1 bacteria, vectorless systems, Lipoteichoic Acid, or AAV vectors); ABSL2 for 3 days (mice administered lentiviral, rabies or pseudorabies viral vectors); ABSL2 for the duration (rodents administered rDNA-modified RG1 bacteria or human-derived substances). No work involving animal-derived substances or plants.

Changes: Added work with *Citrobacter rodentium* (BSL2) with administration to mice (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

10. IBCA00000653_AR04

O'Brien, Patrick – Amendment

Current approval: BSL1 (plasmid vectors and vectorless systems). No work involving infectious agents, biological toxins, human- or animal-derived substances, animals or plants.

Changes: Added work with human-derived substances (BSL2) and updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application.

11. *This application was handled separately due to a conflict of interest.*

12. *This application was handled separately due to a conflict of interest.*

13. IBCA00000793_AR04

Zaslavsky, Alexander – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL2 for the duration (mice administered human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added new gene elements in lentiviral vectors (BSL2), additional human-derived substances (BSL2), and updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

14. IBCA00000815_AR03

Fearon, Eric – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (lentivirus and MoLV vectors); BSL2 (human-

derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA modified animal cells). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added new gene elements in plasmid vectors (BSL1) and lentivirus vectors (BSL2) and additional transgenic mice (ABSL1). Also updated risk mitigation practices (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

15. IBCA00000836_AR05

Cianfrocco, Michael – Renewal

Current approval: BSL1 (plasmid vectors and baculovirus vectors); BSL2 (baculovirus vectors); BSL2 (human-derived substances); BSL2 (animal-derived substances: non-human primates). No work involving infectious agents, biological toxins, animals or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

16. IBCA00000837_AR06

Kohn, David – Renewal

Current approval: BSL1 (plasmid and phage vectors); BSL2 (adenovirus, lentivirus, and MoLV vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA modified animal cells, adenovirus vectors, and retrovirus vectors); ABSL2 for 3 days (mice administered adenovirus vectors); ABSL2 for the duration (mice administered human-derived substances, rDNA modified human cells, or retrovirus vectors). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added work with additional human cells (BSL2) and updated risk mitigation practices (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable re-review by one reviewer.

17. IBCA00000893_AR18

Kim, Chang – Renewal

Current approval: BSL1 (plasmid and MSCV vectors); BSL2 (MoLV vectors); BSL2 (Listeria monocytogenes, Citrobacter rodentium, Lymphocytic choriomeningitis (non-neurotropic) strains, and Flaviviruses); BSL2 (Staphylococcal enterotoxins, Pertussis toxin, Cholera toxin, and LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA modified animal cells, Pertussis toxin, Cholera toxin, or LPS); ABSL2 for the duration (mice administered Citrobacter rodentium, Listeria monocytogenes, or LCMV). No work involving animal-derived substances or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

18. IBCA00001018_AR10

Bottino, Marco – Amendment

Current approval: BSL2 (RG2 bacteria); BSL2 (LPS); BSL2 (human-derived substances); BSL2

(animal-derived substances: swine); ABSL1 (immunodeficient mice); ABSL1 (rats administered LPS); ABSL2 for the duration (rats administered RG2 bacteria). No work involving rDNA or plants.

Changes: Added work with *Streptococcus mutans* (BSL2) with administration to rats (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

19. IBCA00001197_AR03

Bridwell-Rabb, Jennifer – Amendment

Current approval: BSL1 (plasmid vectors); BSL2 (Saxitoxin). No work involving infectious agents, human- or animal-derived substances, animals or plants.

Changes: Added new gene elements in plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

20. *This application was tabled.*

21. IBCA00001786_AR01

Pandey, Aditya – Renewal

Current approval: BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL2 for the duration (mice administered human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

22. IBCA00002011_AR06

Surface, Lauren – Amendment

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added work with adenoviral vectors (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

23. IBCA00002075_AR05

Brunaugh, Ashlee – Amendment

Current approval: BSL2 (RG2 bacteria and rhinovirus); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL2 for the duration (mice administered RG2 bacteria and rhinovirus). No work involving rDNA, biological toxins, animal-derived substances, or plants.

Changes: Added work with *E. coli* K-12 plasmid vectors (BSL1), *Mycobacterium* plasmid vectors (BSL2), and administration of rDNA modified RG2 bacteria to mice (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

24. IBCA00002168_AR03**Carpenter, Eileen – Amendment**

Current approval: BSL1 (plasmid vectors); BSL2 (lentivirus vectors); BSL2 (human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Added new gene elements in plasmid vectors (BSL1) and work with MSCV vectors (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application.

25. *This application was handled separately due to a conflict of interest.*

26. IBCA00002397_AR09**Li, Jiahe – Renewal**

Current approval: BSL1 (plasmid vectors); BSL2 (lentivirus vectors and plasmid vectors in RG2 host); BSL1 (RG1 bacteria); BSL2 (RG2 bacteria); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered LPS, rDNA modified animal cells, plasmid vectors, RG1 bacteria, or rDNA modified RG1 bacteria); ABSL2 for the duration (mice administered human-derived substances, rDNA modified human-derived substances, RG2 bacteria, or rDNA modified RG2 bacteria). No work involving animal-derived substances or plants.

Changes: Added work with an additional plasmid vector (BSL1) and *Bifidobacterium longum* (BSL1), with administration of *Bifidobacterium longum* and recombinant *Bifidobacterium longum* to mice (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

27. IBCA00002412_AR02**Hara, Toshiro – Renewal**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered lentivirus vectors or rDNA modified animal derived cells); ABSL2 for the duration (mice administered human-derived substances or rDNA modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

28. IBCA00002421_AR06**Zhu, Guizhi – Renewal**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (Pertussis toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, Pertussis toxin, or rDNA-modified animal cells); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1

and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

29. IBCA00002453_AR02

Reinert, Rachel – Renewal

Current approval: BSL1 (vectorless systems, plasmid, and AAV vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added additional transgenic mice (ABSL1) and new gene elements in plasmid vectors and vectorless systems (BSL1), and in lentiviral vectors (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

30. IBCA00002507_AR01

Burgess, Helen – Renewal

Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Updated work with human-derived substances (BSL2), and risk mitigation practices (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

31. IBCA00003013_AR02

Shin, Jae Won – Amendment

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, rDNA-modified animal cells, or LPS). No work involving infectious agents, animal-derived substances, or plants.

Changes: Added new gene elements in plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

32. IBCA00003210

Merz, Lauren - Initial Application

Proposed: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

33. IBCA00003225

Knutson, Steven - Initial Application

Proposed: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus vectors); BSL2 (human-derived substances); ABSL2 for the duration (mice administered rDNA modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

Motion: Joyce Lai motioned to approve the (29) IBC applications listed above at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Alex Rickard seconded the motion.

Vote: All in favor.

BSL1 Applications

The following BSL1 applications were considered by the committee and voted upon.

34. IBCA00000852_AR05

Diba, Kamran – Renewal

Current approval: BSL1 (AAV vectors); ABSL1 (transgenic rodents); ABSL1 (rodents administered AAV vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

35. IBCA00002449_AR02

Shan, Libo – Renewal

Current approval: BSL1 (plasmid vectors and tobacco rattle virus vectors); BSL1 (RG1 fungi and bacteria); BL1-P (transgenic plants); BL1-P (plants administered plasmid vectors, tobacco rattle virus vectors, RG1 bacteria, or RG1 fungi). No work involving biological toxins, human- or animal-derived substances, or animals.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed plant containment level is considered appropriate.

Motion: Huiira Kopera motioned to approve the (2) IBC applications listed above at the containment levels agreed upon.

Second: Stephen Rapundalo seconded the motion.

Vote: All in favor

Tabled Applications

The following applications were tabled.

20. IBCA00001546_AR03

Udager, Aaron – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (adenoviral, lentiviral and AAV vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells); ABSL2 for 3 days (mice administered AAV, lentiviral, or adenoviral vectors); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: Tabled.

6. Matters Arising

There were no matters arising.